Kurs kaydını izlemek için tıklayınız.

• 5. Modül Programı
• Dose-Intensive Chemotherapy Including Rituximab in Burkitt’s Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status
• Intensive Chemotherapy with and without Cranial Radiation for Burkitt Leukemia and Lymphoma
• A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
• An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study
• Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity
• Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia
• Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
• Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002
• A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma
• Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma
• The treatment of Burkitt lymphoma in adults
• HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis
• Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia
• Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
• Low-Intensity Therapy in Adults with Burkitt’s Lymphoma
• Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
• Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, Unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
• Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol
• B Lymphoblastic Leukemia/Lymphoma with Burkitt-like morphology and IGH/MYC rearrangement: report of three cases in adult patients
• Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
• Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
• Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab
• Acute lym pho blas tic leu ke mia in older adults: cur tain call for con ven tional che mo ther apy ?
• Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
• How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults
• Philadelphia-Like Acute Lymphoblastic Leukemia: A Systematic Review
• First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)
• Treatment of Pediatric Burkitt Lymphoma in Turkey
• Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
• Burkitt Leukemia With Precursor B-Cell Immunophenotype and Dual Translocation of t(14;18) and t(8;14) in a Child: Case Report and Review of the Literature
• Kraniyal sinir felçleriyle baflvuran alt› yafl›nda erkek çocuk
• Have any strategies in Ph-like ALL been shown to be effective?
• Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
• Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies
• Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
• How I investigate minimal residual disease in acute lymphoblastic leukemia